rs13277113 — BLK

Regulatory variant upstream of BLK that reduces B-lymphoid tyrosine kinase expression, impairing B-cell tolerance and raising risk for SLE, Sjögren's syndrome, systemic sclerosis, and rheumatoid arthritis

See your personal result for BLK

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

BLK rs13277113 — The B-Cell Signaling Dimmer

BLK (B-lymphoid tyrosine kinase)11 BLK (B-lymphoid tyrosine kinase)
A Src-family non-receptor tyrosine kinase expressed almost exclusively in B cells and plasmacytoid dendritic cells encodes a kinase that plays a critical role in B-cell receptor (BCR) signaling and B-cell development. Acting as an accelerator for BCR-driven activation signals, BLK helps B cells respond to antigen stimulation — but crucially, it also participates in the central tolerance checkpoint22 central tolerance checkpoint
The process by which immature B cells that recognize self-antigens are eliminated or silenced in the bone marrow before they can cause harm that eliminates self-reactive B cells. The rs13277113 SNP sits in the promoter region upstream of the BLK transcription start site: the A risk allele reduces BLK mRNA levels in B-cell lines.

The Mechanism

BLK is a Src-family kinase33 Src-family kinase
A family of non-receptor tyrosine kinases including Src, Fyn, Lck, and Lyn. BLK is the B-cell-specific member expressed at high levels in B cells from the pre-B cell stage onward. Within the B-cell receptor signaling complex, BLK phosphorylates downstream substrates that both activate B-cell responses to antigen and help establish negative selection of self-reactive clones. When BLK expression is reduced by the A allele, this tolerance mechanism is partially impaired: B cells that recognize self-antigens escape deletion more readily. The result is a subtle shift toward B-cell hyperactivation and increased autoantibody production44 increased autoantibody production
Including anti-dsDNA and anti-Smith antibodies characteristic of SLE, and anti-SSA/SSB antibodies in Sjögren's syndrome, the hallmark of multiple systemic autoimmune diseases.

The variant is located at chromosome 8p23.1 in the FAM167A-BLK locus. Notably, the A allele at rs13277113 is also associated with increased expression of the neighboring gene C8orf13/FAM167A55 increased expression of the neighboring gene C8orf13/FAM167A
The risk allele reduces BLK but increases FAM167A expression; the functional consequences of elevated FAM167A remain incompletely characterized, suggesting the regulatory region affects a shared promoter element.

The Evidence

The discovery GWAS66 discovery GWAS
Hom G et al. 2008 — 1,311 SLE cases, 1,783 North American controls; replicated in 793 Swedish cases and 857 Swedish controls published in the New England Journal of Medicine identified rs13277113 as a genome-wide significant SLE susceptibility locus (OR=1.39, P=1×10⁻¹⁰). Crucially, the study also showed that the A allele correlated with reduced BLK mRNA levels in B-cell lines, providing direct mechanistic evidence linking a regulatory variant to altered gene expression to disease risk.

Subsequent meta-analyses have firmly established this association. A 2011 meta-analysis77 2011 meta-analysis
Fan et al. — 11,796 SLE cases and 20,271 controls across six studies found an overall A-allele OR of 1.42 with no publication bias and no heterogeneity, supporting a highly consistent effect. The largest 2017 meta-analysis88 2017 meta-analysis
Song and Lee — 17 studies, 22,701 cases, 36,365 controls confirmed OR=1.36 (P<1×10⁻⁸) consistent across Caucasian, Asian, and African populations. A broader autoimmune disease meta-analysis99 broader autoimmune disease meta-analysis
Zeng et al. 2017 — 24 studies, 31,095 cases, 39,077 controls for rs13277113 covering SLE, RA, Sjögren's, and other conditions found rs13277113 A vs G: OR=1.33 (95% CI 1.27–1.39), with the strongest associations in Asian populations.

Beyond SLE, BLK rs13277113 is associated with systemic sclerosis1010 systemic sclerosis
Gourh P et al. 2009: 1,050 SSc cases and 694 controls (North American) + 589 SSc cases and 722 controls (Spanish) (OR=1.32 U.S., OR=1.20 combined), particularly with the limited cutaneous and anti-centromere antibody subsets. A French cohort meta-analysis1111 meta-analysis
Coustet et al. 2011 — 6,078 individuals; strongest effect in diffuse cutaneous SSc (OR=1.27) found additive effects between BLK and BANK1 in driving systemic sclerosis risk.

Clinical observations add important nuance: a Turkish cohort study found that the GA genotype1212 GA genotype
Pamuk et al. 2017 — 84 SLE patients and 105 controls was present in 48.8% of SLE patients versus 31.4% of controls (p=0.035), and SLE patients with the GA genotype had significantly more disease flares1313 disease flares
Assessed by SELENA-SLEDAI flare index: 70% of GA carriers experienced flares during follow-up.

Practical Implications

Carriers of the A allele — particularly AA homozygotes — have a modestly elevated lifelong background risk for B-cell-driven autoimmune diseases. The most important practical steps are recognizing the early warning signs and ensuring prompt diagnosis if symptoms emerge. The diseases associated with BLK variants — SLE, Sjögren's syndrome, and systemic sclerosis — are all manageable with modern treatments1414 manageable with modern treatments
Including hydroxychloroquine, low-dose corticosteroids, biologics (belimumab, rituximab), and immunomodulatory drugs when caught early, but can cause significant organ damage if untreated.

The genetic risk from rs13277113 is modest in absolute terms — most carriers will not develop autoimmune disease. However, it meaningfully shifts the probability calculation and warrants increased vigilance: unexplained joint pain, persistent fatigue, rashes (especially malar/butterfly rash), Raynaud's phenomenon, persistent dry eyes or mouth, and abnormal inflammatory markers all warrant autoimmune workup in risk-allele carriers.

There are no supplement or dietary interventions proven to counteract BLK-mediated B-cell dysregulation. The actions center on monitoring, early detection, and avoiding immune-modulating triggers where possible.

Interactions

The most clinically relevant epistatic interaction is with BANK1 rs105164871515 BANK1 rs10516487
BANK1 R61H, a missense variant in a B-cell scaffold protein that promotes BCR hyperactivation. In a Mexican Latin-American cohort, individuals carrying risk alleles at both BLK rs13277113 and BANK1 rs10516487 showed an interaction OR of 2.36 (P<0.0001) for primary Sjögren's syndrome — substantially higher than either variant alone. An independent trans-ethnic meta-analysis1616 trans-ethnic meta-analysis
Génin et al. 2013 — 1,915 RA cases and 1,915 controls from France, Spain, and Japan found a gene-gene interaction between BLK rs13277113 and BANK1 rs3733197 in rheumatoid arthritis (P=0.037): in individuals with BLK GG genotype, the BANK1 G allele increased RA risk (OR=1.21). Both BLK and BANK1 converge on B-cell receptor signaling; their co-occurrence appears to push B-cell hyperactivation beyond what either variant achieves alone.

Genotype Interpretations

What each possible genotype means for this variant.

GG Typical BLK Expression Normal

Normal BLK gene activity — typical B-cell tolerance

You carry two copies of the common G allele at BLK rs13277113. Your BLK gene is expressed at normal levels in B cells, supporting typical B-cell receptor signaling and B-cell tolerance checkpoints. About 54% of people globally share this genotype, with higher frequencies in European populations (~57%) and African populations (~78%). Your background genetic risk for BLK-associated autoimmune diseases (SLE, Sjögren's, systemic sclerosis) is at or below population average.

AG One Risk Allele Intermediate

One BLK risk allele — modestly reduced B-cell tolerance signaling

The A allele at rs13277113 is a regulatory variant sitting upstream of the BLK transcription start site. It reduces BLK gene expression in B cells. This modest reduction is enough to shift the B-cell tolerance set-point: self-reactive B cells that would normally be eliminated in the bone marrow survive more often, potentially contributing to autoantibody production years before clinical disease emerges.

The heterozygous AG genotype confers approximately the same per-allele OR as homozygous AA in most studies (consistent with an additive model), meaning your risk elevation is roughly half that of AA individuals. Notable association signals exist for SLE (OR ~1.3–1.5 per A allele), Sjögren's syndrome (OR ~1.35), and systemic sclerosis (OR ~1.20–1.32), most reliably in European and East Asian populations.

AA Two Risk Alleles High Risk

Two BLK risk alleles — meaningfully elevated autoimmune risk

The homozygous AA genotype results in the lowest BLK expression of the three genotypes at this locus. BLK's role in B-cell tolerance means that reduced expression shifts the entire B-cell population toward a more self-reactive baseline. This manifests clinically as elevated autoantibody titers (particularly ANA and anti-dsDNA in SLE; anti-SSA/SSB in Sjögren's) that may be detectable years before clinical autoimmune disease develops — a phenomenon sometimes called the "pre-clinical autoimmunity" phase.

The AA genotype is most prevalent in East Asian populations (A allele frequency ~70%), which correlates with the higher rates of SLE observed in East Asian women globally. In European populations, AA homozygosity occurs in about 6% of individuals and in African populations in approximately 1.4%.

For Sjögren's syndrome, the BLK-BANK1 interaction amplifies risk substantially — if you also carry the BANK1 rs10516487 G allele (risk genotype), consult the interaction notes.